US2009226472A1PendingUtilityA1

Interleukin-4 receptors

61
Individually held — no corporate assignee on recordPriority: Oct 31, 1988Filed: Nov 20, 2007Published: Sep 10, 2009
Est. expiryOct 31, 2008(expired)· nominal 20-yr term from priority
Inventors:Bruce MosleyDavid J. CosmanLinda S. ParkM. Patricia BeckmannCarl J. MarchRejean Idzerda
G01N 33/6869A61P 37/08C07K 16/2866C07K 14/7155A61K 38/00A61P 37/00
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Mammalian Interleukin-4 receptor proteins, DNAs and expression vectors encoding mammalian IL-4 receptors, and processes for producing mammalian IL-4 receptors as products of cell culture, are disclosed. A method for suppressing an IL-4-dependent immune or inflammatory response in a mammal, including a human, by administering an effective amount of soluble IL-4 receptor (sIL-4R) and a suitable diluent or carrier.

Claims

exact text as granted — not AI-modified
1 . An isolated DNA sequence encoding a mammalian IL-4 receptor (IL-4R). 
   
   
       2 . An isolated DNA sequence according to  claim 1  which encodes a human IL-4R comprising the sequence of human IL-4R (1-800). 
   
   
       3 . An isolated DNA sequence according to  claim 3  which encodes a soluble human IL-4R. 
   
   
       4 . An isolated DNA sequence according to  claim 3  which encodes a soluble human IL-4R comprising the sequence of human IL-4R (1-207). 
   
   
       5 . An isolated DNA sequence according to  claim 2  which encodes a soluble human IL-4R comprising the sequence of human IL-4R (1-197). 
   
   
       6 . A recombinant expression vector comprising a DNA sequence according to  claim 1 . 
   
   
       7 . A recombinant expression vector comprising a DNA sequence according to  claim 2 . 
   
   
       8 . A recombinant expression vector comprising a DNA sequence according to  claim 3 . 
   
   
       9 . A recombinant expression vector comprising a DNA sequence according to  claim 4 . 
   
   
       10 . A recombinant expression vector comprising a DNA sequence according to  claim 5 . 
   
   
       11 . A process for preparing a mammalian IL-4 receptor or an analog thereof, comprising culturing a suitable host cell comprising a vector according to  claim 6  under conditions promoting expression. 
   
   
       12 . A process for preparing a human IL-4 receptor or an analog thereof, comprising culturing a suitable host cell comprising a vector according to  claim 9  under conditions promoting expression. 
   
   
       13 . A process for preparing a human IL-4 receptor or an analog thereof, comprising culturing a suitable host cell comprising a vector according to  claim 10  under conditions promoting expression. 
   
   
       14 . A population of eukaryotic cells which express more than 10 4  surface IL-4 receptors per cell. 
   
   
       15 . A population of eukaryotic cells according to  claim 14 , which express more than 10 5  surface IL-4 receptors per cell. 
   
   
       16 . A substantially homogeneous biologically active mammalian IL-4 receptor composition. 
   
   
       17 . A substantially homogeneous biologically active mammalian IL-4 receptor composition according to  claim 16 , consisting essentially of murine IL-4 receptor. 
   
   
       18 . A homogeneous biologically active mammalian IL-4 receptor composition according to  claim 16 , consisting essentially of human IL-4 receptor. 
   
   
       19 . A composition for regulating immune responses in a mammal, comprising administering an effective amount of a composition according to  claim 16 , and a suitable diluent or carrier. 
   
   
       20 . A composition accordingly to  claim 19  having a specific binding activity of at least about 0.01 nanomole IL-4/nanomole IL-4 receptor. 
   
   
       21 . A composition according to  claim 19 , consisting essentially of a substantially homogeneous protein composition comprising human IL-4 receptor in the form of a glycoprotein having a binding affinity (K a ) for human IL-4 of about 1−8×10 9  M −1 , and the N-terminal amino acid sequence Lys Val Leu Gln Glu Pro Thr Cys Val Ser Asp Tyr Met. 
   
   
       22 . An assay method for detection of IL-4 or IL-4 receptor molecules or the interaction thereof, comprising use of a protein composition according to  claim 19 . 
   
   
       23 . Antibodies immunoreactive with mammalian IL-4 receptors. 
   
   
       24 . A homogeneous biologically active IL-4 receptor composition according to  claim 16 , wherein said IL-4 receptor is capable of retaining IL-4 binding activity when bound to a solid support. 
   
   
       25 . A method for suppressing or inhibiting an IL-4-mediated immune or inflammatory response in a mammal, including a human, which comprises:
 administering an amount of soluble IL-4 receptor (sIL-4R) and a suitable diluent or carrier effective to suppress or inhibit the IL-4-mediated immune or inflammatory response.   
   
   
       26 . A method for suppressing or inhibiting an alloantigen induced IL-4-mediated immune or inflammatory response in a mammal, including a human, which comprises:
 administering an amount of soluble IL-4 receptor (sIL-4R) and a suitable diluent or carrier effective to suppress or inhibit the alloantigen induced IL-4-mediated immune or inflammatory response.   
   
   
       27 . A method for suppressing IL-4-mediated proliferation of lymphocytes in a mammal, including a human, which comprises:
 administering an amount of soluble IL-4 receptor (sIL-4R) and a suitable diluent or carrier effective to suppress the IL-4-mediated proliferation of lymphocytes.   
   
   
       28 . A method for suppressing allograft rejection in a mammal, including a human, which comprises:
 administering an amount of soluble IL-4 receptor (sIL-4R) and a suitable diluent or carrier effective to suppress the allograft rejection.   
   
   
       29 . A method for suppressing allograft rejection according to  claim 28 , wherein the allograft comprises tissue from an organ selected from the group consisting of skin, kidney, heart, lung, liver and pancreas. 
   
   
       30 . A method for suppressing antibody production in a mammal, including a human, which comprises:
 administering an amount of soluble IL-4 receptor (sIL-4R) and a suitable diluent or carrier effective to suppress the antibody production.   
   
   
       31 . A method for suppressing antibody production in a mammal according to  claim 30 , wherein the antibodies are IgE antibodies. 
   
   
       32 . A method for suppressing an allergic or asthmatic reaction in a mammal, including a human, which comprises:
 administering an amount of soluble IL-4 receptor (sIL-4R) and a suitable diluent or carrier effective to suppress the allergic asthmatic reaction.   
   
   
       33 . A method for suppressing bone marrow transplant failure in a mammal, including a human, which comprises:
 administering an amount of soluble IL-4 receptor (sIL-4R) and a suitable diluent or carrier effective to suppress the bone marrow transplant failure.

Join the waitlist — get patent alerts

Track US2009226472A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.